-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alexion Pharma recently announced the positive top-line results of the Phase 3 evaluation of Ultomiris (ravulizumab-cwvz) in the treatment of adult patients with systemic myasthenia gravis (gMG)
Original source: Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
Original title: New drug for systemic myasthenia gravis (gMG)! Alexion long-acting C5 inhibitor Ultomiris phase 3 clinical success: onset of effect in 1 week, efficacy lasting for 52 weeks!